Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Financial Results (Oct 23, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed October 23, 2025
Period End
October 23, 2025
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Feb ’18Feb ’18
  2. Leadership change8-K · May ’20May ’20
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed October 23, 2025. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. reported third-quarter 2025 net sales of $804.6 milliona, up 7.7% from the prior year, with organic growth of 5.0%.

Net income was $140.0 millionb, and diluted EPS was $1.92 versus $1.85 a year earlier. Adjusted diluted EPS was $1.96, compared with $1.85 in the same period last year. Growth was led by HVP Components, which reached $390.0 million in net sales, up 16.3% (13.3% organic), and represented 48% of total company net sales.

HVP Delivery Devices declined 15.7%, reflecting a one-time incentive fee of approximately $19 millionc earned in the third quarter of 2024. Proprietary Products net sales were $647.5 million, up 7.7%, and Contract-Manufactured Products net sales were $157.1 million, up 8.0%. The company raised its full-year 2025 guidance.

Net sales are now expected to be $3.060 billion to $3.070 billiond, up from $3.040 billion to $3.060 billion, with organic net sales growth now expected at 3.75% to 4.0%, up from 3.0% to 3.75%. Adjusted diluted EPS guidance rose to $7.06 to $7.11, from $6.65 to $6.85. Capital spending guidance is unchanged at $275 million.

For the fourth quarter of 2025, West introduced net sales guidance of $790 million to $800 million and adjusted diluted EPS guidance of $1.81 to $1.86. For the first nine months of 2025, operating cash flow was $503.7 million, up 8.7%, and free cash flow, defined as operating cash flow minus capital expenditures, was $293.9 million, up 53.7%. Capital expenditures were $209.8 million, down 22.9%.

During the nine months, the company repurchased 552,593 shares for $134.0 million. Cash and cash equivalents were $628.5 million at September 30, 2025. The press release also highlights the recent appointment of Robert McMahon as Chief Financial Officer.

02—Key points

Key Highlights

  1. Q3 2025 net sales of $804.6 million rose 7.7% (5.0% organic), and diluted EPS was $1.92 versus $1.85 a year earlier.
  2. Adjusted diluted EPS of $1.96 for Q3 2025 compared with $1.85 in Q3 2024.
  3. HVP Components net sales of $390.0 million grew 16.3% (13.3% organic) and accounted for 48% of total company net sales.
  4. HVP Delivery Devices net sales fell 15.7% due to a one-time incentive fee of approximately $19 million earned in Q3 2024.
  5. Full-year 2025 net sales guidance raised to $3.060 billion to $3.070 billion, and adjusted diluted EPS guidance raised to $7.06 to $7.11 from $6.65 to $6.85.
  6. Q4 2025 guidance calls for net sales of $790 million to $800 million and adjusted diluted EPS of $1.81 to $1.86.
  7. Nine-month free cash flow of $293.9 million rose 53.7%, and $134.0 million was spent repurchasing 552,593 shares.

03—Questions

Frequently Asked Questions

  1. What drove West's third-quarter 2025 sales growth?

    Net sales of $804.6 million rose 7.7%, with organic growth of 5.0%. HVP Components, up 16.3% to $390.0 million, was the main driver, supported by strength in Westar and Envision products. Contract-Manufactured Products grew 8.0%, driven by sales of self-injection devices for obesity and diabetes, partially offset by lower healthcare diagnostic device sales.

  2. Why did HVP Delivery Devices sales decline?

    HVP Delivery Devices net sales decreased 15.7% to $99.1 million, and were down 16.7% on an organic basis. The filing attributes the decline to a one-time incentive fee of approximately $19 million earned in the third quarter of 2024.

  3. How did full-year 2025 guidance change?

    Net sales guidance was raised to $3.060 billion to $3.070 billion from $3.040 billion to $3.060 billion, and organic net sales growth is now expected at 3.75% to 4.0%, up from 3.0% to 3.75%. Adjusted diluted EPS guidance increased to $7.06 to $7.11 from $6.65 to $6.85. Capital spending guidance is unchanged at $275 million.

  4. What is the outlook for the fourth quarter of 2025?

    West introduced fourth-quarter 2025 net sales guidance of $790 million to $800 million, with organic net sales growth expected at 1.0% to 2.3%. Adjusted diluted EPS guidance is $1.81 to $1.86, and it assumes a tax rate of approximately 21% and excludes potential tax benefits from stock-based compensation.

  5. How strong was cash generation and capital return in the first nine months of 2025?

    Operating cash flow was $503.7 million, up 8.7%, and capital expenditures were $209.8 million, down 22.9%. Free cash flow was $293.9 million, up 53.7%. The company repurchased 552,593 shares for $134.0 million at an average price of $242.55 per share, and cash and cash equivalents totaled $628.5 million at September 30, 2025.

04—Continue

← View all 8-K filings